NOVT

In the past six months (April 2026 - October 2026), Novanta's stock was impacted by several events. The company announced strong Q1 2026 earnings in May, exceeding expectations with significant revenue growth and a surge in bookings. In July, Novanta completed the strategic acquisition of Riverpoint Medical, which is expected to double its recurring medical consumables business and increase medical end-market exposure. Q2 2026 financial results in August also surpassed Wall Street's revenue and adjusted EPS expectations, attributed to new product revenue and operational improvements. Novanta presented at several healthcare conferences between June and September, with one presentation reportedly leading to a stock pullback. September saw insider selling, with a director selling shares under a preset plan, contributing to $11.6 million in insider sales over the past year. In October, Zacks Research downgraded Novanta's stock to "hold," although other analysts maintained positive ratings. Despite some pullbacks in September and October due to broader market weakness and profit-taking, Novanta's stock price had gained 42.3% over the past 12 months as of October 7, 2026.